Simo Josué Louokdom, Tuono Romaric De Manfouo, Manewa Bendzigho Tatsiane, Seuko Maryline Njopwouo, Matchein Yolande Nathalie, Tayou Claude Tagny
Faculty of Health Sciences, University of Montagnes, Bangangté, West Cameroon, Cameroon.
Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon.
Adv Hematol. 2025 Aug 6;2025:3328539. doi: 10.1155/ah/3328539. eCollection 2025.
Cytopenias are a frequent concern in the management of patients living with HIV/AIDS (PLWHA). The study objective was to determine the burden of anemia and cytopenia among PLWHA on antiretroviral treatment in the Cameroonian context and to identify the associated factors. We conducted an analytical and cross-sectional study over 4 months. The study population consisted of PLWHAs on ARV treatment at the DREAM Center in Dschang. Blood samples were taken in EDTA and dry tubes. Complete blood counts, CD4 count, ferritin, and serum iron measurements were performed using flow cytometry, ELISA, and spectrophotometry methods. The results were recorded in an Excel spreadsheet and analyzed using SPSS statistical software. 198 PLWHAs on ARV treatment with extremes aged 15-75 years were included in this study, with a sex ratio of 0.48 in favor of women. The frequency of anemia was 32.32%. Triple therapy (3TC + TDF + DLV) was the most commonly used regimen (75.76%). The frequency of anemias was 32.32%, and they were mainly normocytic and normochromic. 8.08% of the population had leukopenia, and 9.09% had thrombocytopenia. Advanced immunodeficiency (CD4 level: 200-500 C/mm) was identified as a predictive factor for anemia in PLWH in this study (OR = 2.88 [0.82-10.11]; = 0.097). Cytopenias in general, and anemias, in particular, are very common in patients with HIV/AIDS. These results raise the need for adequate follow-up of the sick population to limit the effects of these cytopenias for a healthier life of patients.
血细胞减少是艾滋病毒/艾滋病患者(PLWHA)管理中经常关注的问题。本研究的目的是确定喀麦隆接受抗逆转录病毒治疗的艾滋病毒/艾滋病患者中贫血和血细胞减少的负担,并确定相关因素。我们进行了一项为期4个月的分析性横断面研究。研究人群包括在雅温得DREAM中心接受抗逆转录病毒治疗的艾滋病毒/艾滋病患者。在乙二胺四乙酸(EDTA)管和干燥管中采集血样。使用流式细胞术、酶联免疫吸附测定(ELISA)和分光光度法进行全血细胞计数、CD4计数、铁蛋白和血清铁测量。结果记录在Excel电子表格中,并使用SPSS统计软件进行分析。本研究纳入了198名年龄在15至75岁之间、接受抗逆转录病毒治疗的艾滋病毒/艾滋病患者,性别比为0.48,女性占优。贫血的发生率为32.32%。三联疗法(3TC + TDF + DLV)是最常用的治疗方案(75.76%)。贫血的发生率为32.32%,主要为正细胞正色素性贫血。8.08%的人群有白细胞减少症,9.09%的人群有血小板减少症。在本研究中,晚期免疫缺陷(CD4水平:200 - 500个细胞/mm)被确定为艾滋病毒/艾滋病患者贫血的预测因素(比值比[OR] = 2.88 [0.82 - 10.11];P = 0.097)。一般来说,血细胞减少,尤其是贫血,在艾滋病毒/艾滋病患者中非常常见。这些结果表明需要对患者群体进行充分的随访,以限制这些血细胞减少的影响,使患者过上更健康的生活。